Figure 1
Multivariate cox regression hazard model for factors affecting cancer-specific survival in patients with APC_
| Multivariate | ||||
|---|---|---|---|---|
| HR | 95.0% CI | |||
| Variable | Lower | upper | p-value | |
| Age | 0.994 | 0.962 | 1.028 | 0.7 |
| Sex | 0.896 | 0.614 | 1.309 | 0.5 |
| vitamin D level | 0.827 | 0.569 | 1.248 | 0.6 |
| Vitamin D level insufficiency | 1.233 | 0.777 | 1.975 | 0.3 |
| Vitamin D level deficiency | 1.062 | 0.646 | 1.746 | 0.8 |
| Pathology GI | 1.027 | 0.569 | 1.855 | 0.9 |
| Pathology GII&GIII | 0.865 | 0.258 | 2.901 | 0.8 |
| Site(head) | 0.804 | 0.539 | 1.197 | 0.2 |
| Site(Body) | 0.934 | 0.370 | 0.588 | 0.02 |
| Tumor size | 1.380 | 0.610 | 1.219 | 0.7 |
| CA19.9 | 1.000 | 1.000 | 1.000 | 0.9 |
| Liver metastases | 0.892 | 0.544 | 1.461 | 0.6 |
| Lung metastases | 1.210 | 0.792 | 1.848 | 0.3 |
| Peritoneal metastasis | 0.545 | 0.364 | 0.816 | 0.003 |
| ECOG | ||||
| PS1 | 0.103 | 0.877 | 0.394 | 0.7 |
| PS2 | 0.020 | 1.070 | 0.425 | 0.8 |
| PS3 | 3.915 | 3.054 | 1.001 | 0.04 |
| PS4 | 8.319 | 7.383 | 1.898 | 0.004 |
| Treatment type | 0 | 0 | 0 | 0 |
Relation between vitamin D3 level and overall survival among 176 pancreatic carcinoma patients_
| N | Mean OS (months) | Median OS (months) | Overall Survival (OS) | p-value† | |||||
|---|---|---|---|---|---|---|---|---|---|
| Estimate (95%CI) | Estimate (95%CI) | 6 month | 12 month | 18 month | |||||
| All patients | 176 | 7.72mon | (6.95–8.48) | 7.60mon | (5.60–9.59) | 55.7% | 26.1% | 0% | ----- |
| Vitamin D3 level | |||||||||
| Normal | 70 | 10.57mon | (9.48–11.65) | 11.36mon | (10.10–12.63) | 78.6% | 44.3% | 0% | <0.001 |
| Insufficiency | 50 | 6.77mon | (5.48–8.06) | 7.03mon | (5.10–8.95) | 56% | 16% | 0% | |
| Deficiency | 56 | 5.01mon | (3.82–6.20) | 2.66mon | (2.14–3.19) | 26.8% | 12.5% | 0% | |
Relation between clinicopathological features, outcome and vitamin D3 level among 176 pancreatic carcinoma patients_
| Characteristics | Normal | Insufficiency | Deficiency | p-value | |||
|---|---|---|---|---|---|---|---|
| (N=70) | (N=50) | (N=56) | |||||
| No. | % | No. | % | No. | % | ||
| Age (years) | |||||||
| Mean ±SD | 57.87±7.60 | 61.64±4.52 | 64.10±8.92 | <0.001‡ | |||
| Median (Range) | 59 (39 – 80) | 61 (52 – 75) | 65 (30 – 80) | ||||
| Sex | |||||||
| Male | 43 | 61.4 | 31 | 62 | 31 | 55.4 | 0.728‡ |
| Female | 27 | 38.6 | 19 | 38 | 25 | 44.6 | |
| Grade | |||||||
| Grade I | 22 | 31.4 | 6 | 12 | 1 | 1.8 | <0.001‡ |
| Grade II | 45 | 64.3 | 43 | 68 | 26 | 46.4 | |
| Grade III | 3 | 4.3 | 10 | 20 | 29 | 51.8 | |
| Site | 32 | 45.7 | 13 | 26 | 30 | 53.6 | 0.059‡ |
| Head | |||||||
| Body | 20 | 28.6 | 21 | 42 | 16 | 28.6 | |
| Tail | 18 | 25.7 | 16 | 32 | 10 | 17.9 | |
| Tumor size | |||||||
| T1 | 1 | 1.4 | 0 | 0 | 0 | 0 | <0.001‡ |
| T2 | 26 | 37.1 | 10 | 20 | 7 | 12.5 | |
| T3 | 39 | 55.7 | 30 | 60 | 21 | 37.5 | |
| T4 | 4 | 5.7 | 10 | 20 | 28 | 50 | |
| Site of metastasis | |||||||
| Peritoneal | 43 | 61.4 | 28 | 56 | 38 | 67.9 | 0.452‡ |
| Liver | 45 | 64.3 | 36 | 72 | 54 | 96.4 | <0.001‡ |
| Lung | 18 | 25.7 | 15 | 30 | 21 | 37.5 | 0.359‡ |
| Bone | 0 | 0 | 3 | 6 | 0 | 0 | 0.021‡ |
| ECOG PS | |||||||
| ECOG 0 | 8 | 11.4 | 2 | 4 | 0 | 0 | <0.001‡ |
| ECOG 1 | 42 | 60 | 18 | 36 | 12 | 21.4 | |
| ECOG 2 | 18 | 25.7 | 24 | 48 | 22 | 39.3 | |
| ECOG 3 | 2 | 2.9 | 5 | 10 | 16 | 28.6 | |
| ECOG 4 | 0 | 0 | 1 | 2 | 6 | 10.7 | |
| CA 19-9 | 600.35±974.71 | 1126.54±1342.46 | 1422.60±1002.65 | <0.001Ÿ | |||
| Mean ±SD | |||||||
| Median (Range) | 237.50 (21 – 6987) | 745 (48 – 7896) | 1459 (21 – 4928) | ||||
| Treatment type | |||||||
| Chemotherapy | 68 | 97.1 | 44 | 88 | 34 | 60.7 | 0.000 |
| Best supportive care | 2 | 2.9 | 6 | 12 | 22 | 39.3 | |
| Response | |||||||
| PR | 37 | 52.9 | 8 | 16 | 5 | 8.9 | <0.001‡ |
| SD | 21 | 30 | 19 | 38 | 8 | 14.3 | |
| PD | 12 | 17.1 | 23 | 46 | 43 | 76.8 | |
Clinicopathological features among 176 advanced pancreatic carcinoma patients_
| All | ||
|---|---|---|
| Characteristics | (N=176) | |
| No. | % | |
| Age (years) | ||
| Mean± SD | 60.92±7.79 | |
| Median (Range) | 61 (30 – 80) | |
| Sex | ||
| Male | 105 | 59.7 |
| Female | 71 | 40.3 |
| Grade | ||
| Grade I | 29 | 16.7 |
| Grade II | 105 | 59.7 |
| Grade III | 42 | 23.9 |
| Site | ||
| Head | 75 | 42.6 |
| Body | 57 | 32.4 |
| Tail | 44 | 25 |
| Peritoneal nodules | 109 | 61.9 |
| Liver metastasis | 135 | 76.7 |
| Lung metastasis | 54 | 30.7 |
| Bone | 3 | 1.7 |
| Treatment type Chemotherapy | 146 | 83 |
| Best supportive care | 30 | 17 |
| ECOG PS | ||
| ECOG 0 | 10 | 5.7 |
| ECOG 1 | 72 | 40.9 |
| ECOG 2 | 64 | 36.4 |
| ECOG 3 | 23 | 13.1 |
| ECOG 4 | 7 | 4 |
| Vitamin D3 level | ||
| Normal | 70 | 39.8 |
| Insufficiency | 50 | 28.4 |
| Deficiency | 56 | 31.8 |
| CA 19-9 | ||
| Mean ±SD | 1011.46±1149.19 | |
| Median (Range) | 698 (21 – 7896) | |
| Response PR | 50 | 28.4 |
| SD | 48 | 27.3 |
| PD | 78 | 44.3 |
| Follow-up (months) Mean± SD | 7.72±5.17 | |
| Median (Range) | 7.61 (0.63 – 18.60) | |